2,321 results on '"Johnson, Melissa A."'
Search Results
2. Part Three. Conclusions
3. Chapter 9. Special Events, Controlled Tools, and Other Tactics
4. Chapter 8. Media Relations and Digital Newsrooms
5. Chapter 7. Social Media: Interactivity and Engagement
6. Chapter 6. Museum Websites and Multimodal Communication
7. Chapter 5. Public Relations Planning and Evaluation
8. Part Two. Museum Public Relations Planning, Implementation, and Evaluation
9. Chapter 2. Communicating Identity in Public Relations: Culture-Centered Museum Practitioners Speak
10. Chapter 4. Visual Intercultural Communication: Incorporating Cultural Aesthetics in Public Relations
11. Acknowledgments
12. Chapter 1. Communicating Cultural Identity: The Role of Museum Public Relations
13. Chapter 3. Communicating Counterstereotypes and Cultural Attractiveness: Furthering Public Relations' Societal Role
14. Cover
15. Part One. Identity and Museum Public Relations
16. Title Page, Copyright, Dedication
17. References
18. Appendix A. Methodology: Interviews
19. Index
20. Appendix B. Methodology: Content Analyses
21. Back Cover
22. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer.
23. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
24. Manipulating mitochondrial electron flow enhances tumor immunogenicity.
25. An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs
26. Exploring the biopsychosocial impact of hypermobility spectrum disorders and Ehlers-Danlos syndrome in an adult population: a protocol for a scoping review
27. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
28. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
29. Psychological interventions to improve pain, fatigue, anxiety, depression, and quality of life in children and adults with hypermobility spectrum disorders and Ehlers-Danlos syndrome: a systematic review
30. One-pot and One-step Cu(0)-mediated Reversible-Deactivation Radical Polymerization of N-Isopropylacrylamide (NIPAM) in Water
31. Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours
32. Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
33. The Use of a Viability Index as a Better Measure of Departmental and Program Strength. The AIR Professional File, Spring 2021. Article 152
34. Apragmatism: The Renewal of a Label for Communication Disorders Associated with Right Hemisphere Brain Damage
35. A Student Stops by My Classroom, and: Deciphering Grief
36. Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
37. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
38. Digital Skills in Pandemic Times: How State Policymakers Can Help Workers and Businesses Adapt in a Changing Economy
39. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results
40. The Roadmap for Racial Equity: An Imperative for Workforce Development Advocates. Special Edition: Immigrants and English Learners
41. Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients
42. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
43. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung CancerHER3-DXd in EGFR TKI–Resistant EGFR-Mutated NSCLC
44. Speechless
45. A Man I Didn’t Sleep with Asked What Word Defined Me
46. Assessing Discourse Ability in Adults with Right Hemisphere Damage
47. A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
48. The biopsychosocial impact of hypermobility spectrum disorders in adults: a scoping review
49. Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours
50. Backbone cationized highly branched poly(β-amino ester)s as enhanced delivery vectors in non-viral gene therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.